Table of Contents
Corrigendum

A corrigendum for this article has been published. To view the corrigendum, please click here.

International Scholarly Research Notices
Volume 2014, Article ID 184278, 10 pages
http://dx.doi.org/10.1155/2014/184278
Clinical Study

Study on the Therapeutic Benefit on Lactoferrin in Patients with Colorectal Cancer Receiving Chemotherapy

1Faculty of Pharmacy, Tanta University, Tanta, Egypt
2Pharmacology Department, Faculty of Pharmacy, Tanta University, Tanta, Egypt
3Faculty of Medicine, Menoufiya University, Shibin el-Kawm, Egypt
4Hospital of Menoufiya University, Shibin el-Kawm, Egypt

Received 17 March 2014; Revised 21 July 2014; Accepted 11 August 2014; Published 29 October 2014

Academic Editor: Nicolaas A. Franken

Copyright © 2014 Tarek M. Moastafa et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

A double-blinded parallel randomized controlled clinical trial was conducted on two groups of colorectal cancer patients to study the therapeutic benefit of orally administered bovine lactoferrin (bLF) on colorectal cancer patients having age ranges from 20 to 71 years and who received 5-fluorouracil and leucovorin calcium. Test group (15 patients) received oral bLF 250 mg/day beside chemotherapy for three months. Control group (15 patients) received chemotherapy only. Serum lactoferrin (LF), serum glutathione-s-transferase enzyme (GST), interferon gamma (INF-γ), tumor marker carcinoembryonic antigen (CEA), renal function tests, hepatic function tests, and complete blood count were measured for both groups before and at the end of the trial. Although, there was a significant effect of oral bLF (250 mg/day) that indicated a significant improvement in mean percent of change of all parameters 3 months after treatment, there was no significant difference between results of patients in the test group and patients in the control group after treatment. This result suggests that oral bLF has significant therapeutic effect on colorectal cancer patients. Our study suggests that daily administration of bLF showed a clinically beneficial effect to colorectal cancer patients with better disease prognosis but that needs further looking into.